<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060356</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 11916, 825376</org_study_id>
    <nct_id>NCT03060356</nct_id>
  </id_info>
  <brief_title>Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)</brief_title>
  <official_title>Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma &amp; Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy&#xD;
      for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric&#xD;
      antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred&#xD;
      to as &quot;RNA CART-cMET&quot;) in patients with advanced melanoma or breast carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy&#xD;
      for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric&#xD;
      antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred&#xD;
      to as &quot;RNA CART-cMET&quot;) in patients with advanced melanoma or breast carcinoma. Subjects will&#xD;
      be treated with IV administration of the RNA transduced anti-cMET CAR T cells for a total of&#xD;
      up to six doses over a 2 week period.&#xD;
&#xD;
      Each dose is 1x108 total T cells modified with RNA anti-cMET CAR. All subjects in both the&#xD;
      melanoma and breast carcinoma arms will receive up to 6 doses of RNA CART-cMET cells, with no&#xD;
      lymphodepleting chemotherapy administered prior to cell infusion Cell numbers are based on&#xD;
      total cells with a portion of them having CAR expression depending on transduction efficiency&#xD;
      and determined by flow cytometry Based on the product release criteria, at least 20% of the&#xD;
      total cells will express the anti-cMET CAR. Treatment limiting toxicity (TLT). Adverse event&#xD;
      reporting will begin at the start of the first dose of RNA CART-cMET and will continue until&#xD;
      4 months after the first infusion, or until another alternative therapy is initiated,&#xD;
      whichever occurs earlier. Subjects will be continually reassessed for evidence of acute and&#xD;
      cumulative toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Halt in funding&#xD;
  </why_stopped>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Actual">March 27, 2020</completion_date>
  <primary_completion_date type="Actual">March 27, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 in melanoma and breast cancer subjects</measure>
    <time_frame>from day 0 - month 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective overall response rate by clinical exam for visible cutaneous tumors</measure>
    <time_frame>day 25 and month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective overall response rate by radiologic imaging using RECIST 1.1</measure>
    <time_frame>day 25 and month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using RECIST 1.1 criteria</measure>
    <time_frame>day -7 and day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using pathological evaluation of resected or biopsied tissue</measure>
    <time_frame>day -7 and day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Melanoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T cells modified with RNA anti -cMET CAR</intervention_name>
    <description>Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains</description>
    <arm_group_label>Breast</arm_group_label>
    <arm_group_label>Melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable histologically confirmed stage III/IV melanoma or metastatic or locally&#xD;
             advanced unresectable ER and PR negative, HER2 neu nonamplified by IHC and/or FISH&#xD;
             breast carcinoma&#xD;
&#xD;
          -  cMET expression in ≥ 30% tumor cells as demonstrated on immunohistochemistry analysis&#xD;
             at the University of Pennsylvania. MET IHC may be performed on tissue from screening&#xD;
             biopsy, or archival slides of a metastatic deposit or primary tumor. Punch biopsy or&#xD;
             percutaneous core biopsy will be offered to obtain tissue as required for this&#xD;
             purpose.&#xD;
&#xD;
          -  Patients must have measureable disease as defined by RECIST 1.1 criteria; must have CT&#xD;
             scan of chest, abdomen, pelvis within 1 month of enrollment that demonstrates&#xD;
             measurable disease by RECIST 1.1 criteria in a tumor other than the one being&#xD;
             potentially biopsied and resected for correlative studies&#xD;
&#xD;
          -  Failure of at least one prior standard of care therapy for advanced stage disease&#xD;
&#xD;
          -  If previously treated with any form of immunotherapy (including agents targeting PD1&#xD;
             or CTLA4, oncolytic viruses) the last administered treatment must be at least 2 weeks&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Males or female patients age &gt; 18 years old&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Clinical Performance Status 0 or 1&#xD;
&#xD;
          -  Adequate hematologic and organ function as defined by:&#xD;
&#xD;
          -  WBC &gt; 3.0 and ANC &gt;1500&#xD;
&#xD;
          -  Plt &gt; 75,000 (no transfusion permitted within 2 weeks to achieve this goal)&#xD;
&#xD;
          -  Hgb &gt; 9 g/dl (transfusions are permitted to achieve this goal)&#xD;
&#xD;
          -  serum creatinine ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  Total bilirubin ≤ 2times upper limit of normal&#xD;
&#xD;
          -  ALT and AST ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  Cardiac ejection fraction of &gt;40% as measured by resting echocardiogram&#xD;
&#xD;
          -  Women of child bearing potential must have a negative serum or urine pregnancy test&#xD;
             and agree to use appropriate contraception from enrollment through the duration of the&#xD;
             trial. Men must agree to use appropriate contraception from enrollment through the&#xD;
             duration of the trial.&#xD;
&#xD;
          -  Patients must provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known metastatic tumor encasing a great vessel or at risk for imminently causing&#xD;
             spinal cord compression&#xD;
&#xD;
          -  Known HIV-1/HIV-2 infection&#xD;
&#xD;
          -  Known active infection with Hepatitis B virus or Hepatitis C virus&#xD;
&#xD;
          -  Received an experimental therapy within 30 days of enrollment&#xD;
&#xD;
          -  Pregnant women or lactating women&#xD;
&#xD;
          -  History of alcohol abuse or illicit drug use within 12 months of enrollment&#xD;
&#xD;
          -  Clinically significant comorbid disease or other underlying condition, including&#xD;
             significant active infection, in the opinion of the PI or sub-investigators, would&#xD;
             contraindicate study therapy or interfere with interpretation of study results&#xD;
&#xD;
          -  Significant psychiatric disorder and/or any other reason in the Investigator's opinion&#xD;
             that would jeopardize protocol compliance or compromise the patient's ability to give&#xD;
             informed consent.&#xD;
&#xD;
          -  Patients with known allergy or hypersensitivity to study product excipients (human&#xD;
             serum albumin, DMSO, and Dextran 40).&#xD;
&#xD;
          -  Patients with clinically apparent arrhythmia, or arrhythmias that are not stable on&#xD;
             medical management within 2 weeks of the Screening/Enrollment visit.&#xD;
&#xD;
          -  Having received prior genetically manipulated T-cells in prior clinical trial&#xD;
&#xD;
          -  History of autoimmune disease (including but not limited to: systemic lupus&#xD;
             erythematosis, Sjogren syndrome, rheumatoid arthritis, psoriasis multiple sclerosis,&#xD;
             inflammatory bowel disease etc).&#xD;
&#xD;
          -  History of immune related adverse event with previous immunotherapy.&#xD;
&#xD;
          -  Chronic use of therapeutic anti-coagulants such as coumadin, heparin, or lovenox&#xD;
&#xD;
          -  Symptomatic or untreated CNS metastases. Pts with previously treated CNS metastases&#xD;
             are eligible if lesions are radiographically/clinically stable without requirement of&#xD;
             steroids within 4 weeks prior to treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara C. Mitchell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennaylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

